Promising eye drug trial halted early – only 16 patients enrolled
NCT ID NCT03845049
First seen Jan 29, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tested whether the drug aflibercept could reduce swelling in the retina caused by a rare eye condition called macular telangiectasia type 1. The trial planned to compare aflibercept to a placebo over six months, but it was stopped early and only enrolled 16 people. Because of the small size and early termination, the results are not strong enough to guide treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU dijon Bourgogne
Dijon, 21000, France
Conditions
Explore the condition pages connected to this study.